Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation [Seeking Alpha]
Galapagos NV - American Depositary Shares (GLPG)
Last galapagos nv - american depositary shares earnings: 10/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
glpg.com/company-overview
Company Research
Source: Seeking Alpha
GLPG's restructuring—discontinuing cell therapy, slashing headcount, and targeting cash flow neutrality by YE2026—positions it as a streamlined M&A platform. Management's M&A-focused pedigree, led by ex-AbbVie dealmakers, signals a pivot from pipeline reliance to transformative business development using its cash war chest. Risks include execution on restructuring, potential value traps if capital is misallocated, and OLCA constraints prohibiting direct capital returns to shareholders. MF3d/iStock via Getty Images Galapagos NV ( GLPG ) provides a complex and uniquely situated opportunity within the biotech sector. The industry has, for many years, evaluated Galapagos via the lens of disappointed clinical results, specifically relating to the early stages of their pipeline This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next
Show less
Read more
Impact Snapshot
Event Time:
GLPG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLPG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLPG alerts
High impacting Galapagos NV - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GLPG
News
- Galapagos (NASDAQ:GLPG) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLPG&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus [Yahoo! Finance]Yahoo! Finance
- Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus ErythematosusGlobeNewswire
- Galapagos (NASDAQ:GLPG) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GLPG&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025GlobeNewswire
GLPG
Earnings
- 11/5/25 - Miss
GLPG
Sec Filings
- 12/18/25 - Form 6-K
- 12/10/25 - Form S-8
- 12/8/25 - Form 6-K
- GLPG's page on the SEC website